新芝生物
(430685)
| 流通市值：4.96亿 | | | 总市值：10.18亿 |
| 流通股本：4458.44万 | | | 总股本：9151.60万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 27,428,266.45 | 190,794,145.37 | 131,282,869.5 | 88,018,599.76 |
| 营业收入 | 27,428,266.45 | 190,794,145.37 | 131,282,869.5 | 88,018,599.76 |
| 二、营业总成本 | 25,910,739.5 | 138,960,711.37 | 96,371,658.16 | 63,501,989.35 |
| 营业成本 | 10,310,916.27 | 66,409,465 | 44,062,119.95 | 28,753,815.7 |
| 税金及附加 | 316,569.48 | 2,507,643.76 | 1,594,784.81 | 990,523.75 |
| 销售费用 | 5,301,395.54 | 27,217,733.24 | 18,229,503.39 | 12,193,231.84 |
| 管理费用 | 5,717,524.24 | 27,619,441.23 | 22,117,799.63 | 15,663,366.04 |
| 研发费用 | 4,782,985.43 | 18,416,864.42 | 13,057,607.36 | 7,995,487.76 |
| 财务费用 | -518,651.46 | -3,210,436.28 | -2,690,156.98 | -2,094,435.74 |
| 其中:利息费用 | 60,008.91 | 334,005.19 | 257,520.4 | 182,149.29 |
| 其中:利息收入 | 550,592.14 | 3,538,364.83 | 2,922,149.66 | 2,218,651.91 |
| 加:公允价值变动收益 | 831,441.11 | 2,959,078.69 | 304,096.05 | 542,845.65 |
| 加:投资收益 | 711,675.67 | 2,973,683.55 | 3,733,453.22 | 1,854,571.65 |
| 资产处置收益 | 23,875.22 | 24,377.27 | 24,377.27 | 14,528.91 |
| 资产减值损失(新) | -328,796.15 | -2,327,580.27 | -777,519.46 | -520,209.69 |
| 信用减值损失(新) | 100,290.91 | 13,701.73 | 46,528.59 | 179,723.41 |
| 其他收益 | 1,144,755.98 | 9,822,821.41 | 6,822,560.22 | 5,073,429.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 4,000,769.69 | 65,299,516.38 | 45,064,707.23 | 31,661,499.6 |
| 加:营业外收入 | 1,154.45 | 12,031,958.69 | 12,026,030.78 | 12,004,373.99 |
| 减:营业外支出 | 260,274.34 | 851,346.78 | 581,282.05 | 541,588.52 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,741,649.8 | 76,480,128.29 | 56,509,455.96 | 43,124,285.07 |
| 减:所得税费用 | 609,562.24 | 9,563,259.33 | 13,460,069.75 | 10,524,057.98 |
| 六、净利润 | 3,132,087.56 | 66,916,868.96 | 43,049,386.21 | 32,600,227.09 |
| 持续经营净利润 | 3,132,087.56 | 66,916,868.96 | 43,049,386.21 | 32,600,227.09 |
| 归属于母公司股东的净利润 | 2,935,721.18 | 58,204,991 | 37,442,324.3 | 28,409,612.23 |
| 少数股东损益 | 196,366.38 | 8,711,877.96 | 5,607,061.91 | 4,190,614.86 |
| (一)基本每股收益 | 0.03 | 0.64 | 0.41 | 0.31 |
| (二)稀释每股收益 | 0.03 | 0.64 | 0.41 | 0.31 |
| 九、综合收益总额 | 3,132,087.56 | 66,916,868.96 | 43,049,386.21 | 32,600,227.09 |
| 归属于母公司股东的综合收益总额 | 2,935,721.18 | 58,204,991 | 37,442,324.3 | 28,409,612.23 |
| 归属于少数股东的综合收益总额 | 196,366.38 | 8,711,877.96 | 5,607,061.91 | 4,190,614.86 |
| 公告日期 | 2024-04-26 | 2024-04-22 | 2023-10-27 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |